Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C174042
http://purl.obolibrary.org/obo/NCIT_C174042
|
|---|---|
| Preferred Name | Imlunestrant |
| Definitions |
An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, imlunestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that results in ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, imlunestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that results in ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells. |
|---|---|
| prefLabel | Imlunestrant
|
| label | Imlunestrant
|
| NCI_META_CUI | CL1407918
|
| PDQ_Closed_Trial_Search_ID | 802339
|
| code | C174042
|
| Has_Target | |
| prefixIRI | NCIT:C174042
|
| in_subset |
See more
See less
|
| Display_Name | Imlunestrant
|
| Preferred_Name | Imlunestrant
|
| FDA_UNII_Code | 9CXQ3PF69U
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Selective Estrogen Receptor Degrader LY3484356
|
| CAS_Registry | 2408840-26-4
|
| NCI_Drug_Dictionary_ID | 802339
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 802339
|
| Semantic_Type | Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |